Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.

Wesley YipDaniel D SjobergLucas M NogueiraAndrew T TraceyRicardo G AlvimPeter A ReiszQuinlan DemacNicole E BenfanteRand W Vanden BergKwanghee KimHikmat Al-AhmadieOscar LinBernard H BochnerGuido DalbagniS Machele DonatEugene J PietzakA Ari HakimiDavid B SolitAvigdor ScherzDean F BajorinJonathan A Coleman

Published in: The Journal of urology (2023)

Vascular-targeted photodynamic therapy with WST-11 has an acceptable safety profile with strong potential as an effective, kidney-sparing endoscopic management option for upper tract urothelial carcinoma. The recently initiated multicenter Phase 3 ENLIGHTED trial (NCT04620239) is expected to provide further evidence on this therapy.

Keyphrases

photodynamic therapy
cancer therapy
phase iii
study protocol
phase ii
clinical trial
drug delivery
open label
randomized controlled trial
double blind
stem cells
robot assisted
cross sectional
risk assessment
climate change
replacement therapy
smoking cessation